| GLP-1 receptor agonists: reminder of the risk of hypoglycaemia and of use only for licensed indications | Medicines and Healthcare products Regulatory Agency | MHRA Drug Safety Update | 2023 | Regulatory document | 1 |
| ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit… | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use | ICH Harmonised Guideline | 2023 | Guideline | 3 |
| ICH Q2(R2) Validation of Analytical Procedures | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use | ICH Harmonised Guideline | 2023 | Guideline | 12 |
| Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised… | Knop FK | The Lancet | 2023 | Journal article | 6 |
| Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised… | Rosenstock J | The Lancet | 2023 | Journal article | 6 |
| Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight… | Sodhi M | JAMA | 2023 | Journal article | 4 |
| Semaglutide and cardiovascular outcomes in obesity without diabetes | Lincoff AM | New England Journal of Medicine | 2023 | Journal article | 12 |
| Semaglutide in patients with heart failure with preserved ejection fraction and obesity | Kosiborod MN | New England Journal of Medicine | 2023 | Journal article | 4 |
| Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase… | Wadden TA | Nature Medicine | 2023 | Journal article | 11 |
| Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a… | Garvey WT | The Lancet | 2023 | Journal article | 11 |
| Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial | Jastreboff AM | New England Journal of Medicine | 2023 | Journal article | 8 |
| WHO Expert Committee on Specifications for Pharmaceutical Preparations — Fifty-seventh report | World Health Organization | WHO Technical Report Series | 2023 | Guideline | 5 |
| Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in… | Dahl D | JAMA | 2022 | Journal article | 1 |
| Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or… | Rubino DM | JAMA | 2022 | Journal article | 20 |
| Once-weekly semaglutide in adolescents with obesity | Weghuber D | New England Journal of Medicine | 2022 | Journal article | 3 |
| Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east… | Kadowaki T | The Lancet Diabetes & Endocrinology | 2022 | Journal article | 0 |
| Tirzepatide once weekly for the treatment of obesity | Jastreboff AM | New England Journal of Medicine | 2022 | Journal article | 17 |
| Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | Garvey WT | Nature Medicine | 2022 | Journal article | 13 |
| Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension | Wilding JPH | Diabetes, Obesity and Metabolism | 2022 | Journal article | 1 |
| Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes | Gerstein HC | New England Journal of Medicine | 2021 | Journal article | 0 |
| Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with… | Rubino D | JAMA | 2021 | Journal article | 14 |
| Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in… | Wadden TA | JAMA | 2021 | Journal article | 13 |
| Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2… | Rosenstock J | The Lancet | 2021 | Journal article | 1 |
| GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art | Nauck MA | Molecular Metabolism | 2021 | Journal article | 18 |
| Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes | Overgaard RV | Cell Reports Medicine | 2021 | Journal article | 6 |
| Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre… | Lau DCW | The Lancet | 2021 | Journal article | 13 |
| Once-weekly semaglutide in adults with overweight or obesity | Wilding JPH | New England Journal of Medicine | 2021 | Journal article | 23 |
| Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2… | Ludvik B | The Lancet | 2021 | Journal article | 1 |
| Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a… | Davies M | The Lancet | 2021 | Journal article | 13 |
| The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | Page MJ | BMJ | 2021 | Journal article | 20 |
| Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a… | Del Prato S | The Lancet | 2021 | Journal article | 1 |
| Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes | Frías JP | New England Journal of Medicine | 2021 | Journal article | 3 |
| How may GIP enhance the therapeutic efficacy of GLP-1? | Samms RJ | Trends in Endocrinology & Metabolism | 2020 | Journal article | 4 |
| LC–MS bioanalysis of intact proteins and peptides | Kang L | Biomedical Chromatography | 2020 | Journal article | 2 |
| Peptides and CCL11 and HMGB1 as differently expressed age-dependent proinflammatory biomarkers of ageing | Khavinson VK | Advances in Gerontology | 2020 | Journal article | 1 |
| The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor… | Urva S | Diabetes, Obesity and Metabolism | 2020 | Journal article | 1 |
| Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions | Thevis M | Expert Review of Proteomics | 2019 | Journal article | 17 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised… | Gerstein HC | The Lancet | 2019 | Journal article | 9 |
| Glucagon-like peptide 1 (GLP-1) | Müller TD | Molecular Metabolism | 2019 | Journal article | 22 |
| Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes | Husain M | New England Journal of Medicine | 2019 | Journal article | 6 |